biogenic amines both in the peripheral and central nervous systems. Unlike AADC, which is common to catecholaminergic and serotoninergic neurons, the preceding enzymes, tyrosine and tryptophan hydroxylases respectively, are site-and substrate-specific. In addition, hydroxylation represents the rate-determining step in amine synthesis and is subjcct t o several mechanisms of regulation. If a bioprecursor of the AADC inhibitor could be persuaded to enter the metabolic chains at the hydroxylation step, not only should this compound havc a selective effect on either catechol or indoleaminc synthesis, but these effects should also depend on thc many factors regulating the activity of the hydroxylases.
a-Monofluoromcthyl-p-tyrosine (MFMT ) is the candidate of choice for catecholamines, and a-monofluoromethyltryptophan (MFMTrp) that for indoleamines. It was verified that neither compound blocks AADC directly and that both compounds were substrates of the corresponding hydroxylases. I n viw, MFMT (as its methyl ester) decreases AADC activity very slowly in the brains of rats or mice after oral administration. Dopamine levels are decreased in a time-and dose-dependent manner, while serotonin levels remain unchanged even at the higher doses of MFMT. The inhibitory effects on catecholamine synthesis increase in response to factors stimulating catecholaminergic activity (haloperidol, yohimbine, physical stress, etc.) and decrease with agents such as apomorphine known to down-regulate aminc synthesis.
a-MFMTrp responds more sluggishly in vivo; it takes three administrations of 100 mg/kg t o see an effect on AADC activity and 5-hydroxyindoleacetic acid levels in rat brains. The influence of factors regulating the activity o f tryptophan hydroxylase was not investigated.
1. Ilioprecrrrsor crppromh to (I brrriii-speeific nioiiouiriiiie oxiduse-A inhibitor. Monoamine oxidase inhibitors (MAO-1) were a well-accepted treatmcnt of depression until they fell into disrepute (at least in U.S.A.), some 10 years ago. One of the rcasons for their disgracc was their propensity to produce hypertensive accidents when taken in combination with foodstuffs containing tyramine (cheese effect). This is due to the undcsirablc inhibition o f MAO-A in the peripheral sympathetic system.
A very elegant solution was proposed by Palfreyman ef ul.
[S]. B-Fluoromcthylene phenethylamines had been shown to be powerful, irreversible inhibitors of MAO-A or -B depending on the substitution of the aromatic ring. They reasoned that the corresponding amino acids ( i t . substituted pfluoromethylene phenylalanines) could be bioprecursors of the M A 0 inhibitors if they were substrates of AADC. Inhibition of AADC in the periphery by carbidopa, would prevent the formation of the fluoroallylamine outside the central nervous system, while allowing more amino acid t o reach the brain.
B-Fluoromethylene-m-tyrosine combines the required characteristics: it is a good substrate of AADC, and the corresponding amine is a powerful inhibitor of M A 0 with a 100-fold preference for MAO-A. After administration of minute amounts ( < 1 mg/kg) to rats, there is a time-and dose-dependent decrease o f M A 0 activity in all organs, MAO-A being the most affected. Co-administration of carbidopa displaces the dose-response curve t o lower doses in the brain and to higher doses in the periphery as expected. When given alone to rats at a dose o f 0 . 1 mg/kg, the amino acid produced a marked elevation o f heart rate upon infusion of tyraminc. Pretreatment of the animals with carbidopa ( 100 mg/kg) abolished, nearly completely. this undesirable tyramine potentiation. This compound is presently being evaluated in the clinic for safety and efficacy as an antidepressant.
Fit fitre rlirectioris
It is clear that no single method. whether chemical modification or vehicle design, can represcnt a gcncral solution for all problems of selective drug delivery. The future lies most probably in a combination of the different approaches. The field of peptide pharmacology which is developing at a stupendous rate represents a challenge t o all drug-dcliveryrelated disciplines in this respect. 
u. K.
Thc oral route is potentially an attractivc approach t o thc delivery of therapeutic drugs and immunogcns. It may be possiblc t o target drugs t o gut-associated tissue and dispcnsc with the requirement for needles, which arc expcnsivc and potentially hazardous. Onc of the main problems associated with the use o f the oral route is obtaining efficient absorbtion of thc drug across thc gut mucosal surfaccs. This is especially true when delivering immunogcns, where the problem o f oral tolerancc is a major consideration. Onc way by which we might learn morc about oral dclivcry is t o study bactcrial pathogcns which havc cvolvcd t o enter the body by this route. Such pathogens include !i~~lttioridici, Sliigc~llcr and Vibrio chokenre. These pathogens cxprcss sophisticated surface and cxtraccllular determinants which cnablc the pathogens t o interact with cukaryotic cclls in a highly specialized manner. They have the capacity t o attach spccificnlly to reccptors on the surfaces o f cpithelial cclls. Some can enter and replicate within these cells and transcytose across the cells to enter decpcr tissues. Some can survive and replicate within cclls of the immune system o r concentrate within immune tissues such as Peycr's patches [ 11. By studying the pathogenic mcchanisnis employed by these organisms, using molecular approaches, it should be possible t o learn how they target themselves to. and survive within. specific tissues. Considerable progress has been made in this area and some of the potential applications will be discussed here. A research plan for the exploitation of bacterial pathogens for oral delivery could he: ((I) the construction o f rationally attenuated bacterial strains derived from virulent pathogens and their use as oral vaccines; ( h ) the use of these rationally ;ittenu;ited strains a s carriers of heterologous antigens and therapeutic molecules; ( c ) the identification of subcomponents of the pathogens involved in cell-cell interactions; and ( ( I ) the use of these subcomponents as non-living delivery vehicles.
l<utioi~ull~ crtr~wrtrting hrrcterirrl putliogcws
A number of key genes have been identified in pathogenic hnctcria which are essential for the survival and replication o f the organism in or on host tissues. o r ;ire involved in mediating tissue damage. Su/iiioiid/ri can also he used to deliver therapeutic proteins to the body. We expressed a human interlcukin-I g~n e in a Salriior~c~llu tiroil vaccine strain (M. Carrier, S. Chatfield & C;. Dougan, unpublished work) and the strain was able t o deliver immunogenic and biologically active human intcrleukin-l t o mice via the oral route.
Nor I -1i r 'ii IS 17ioIogic ' (1 I c l c 4 i lo? A number of proteins expressed by pathogenic bacteria have been shown t o play a role in attachment t o o r pcnctration o f host tissues. Two examples of special interest can be discusscd here.
T h e first example is the LT-H o r CT-H subunits derived from enterotoxigenic Escherichici c d i or C' . c.holcrue. respcctivcly. LT-B is the B-subunit o f E. c d i heat-labile toxin, whereas CT-B is the equivalent subunit of cholera toxin 11 3 ) . LT-B is ii pentameric protein composed o f fivc identical collies of an 1 I SO0 Da polypeptide. LT-B is highly immunogenic. but non-toxic. In is native form it can hind to the surface of epithelial and other eukaryotic cells via the receptor GM ,-ganglioside. LT-B and CT-B are exciting immunogens because they belong to the important group o f antigens which can stimulate strong local secretory as well as general systemic humoral antibody responses after intranasal or oral administriition. CT-B has been shown t o be an cffectivc oral immunogen in man and is currently being considered as a component o f a non-living oral cholera vaccine which will also offer protection against E. c d i diarrhoea.
It is not clear why CT-B or LT-B arc such potent mucosal immunogcns. although it could be linked t o their abilities to bind t o GM ,-ganglioside receptors on surface epithelial cells. However, the ability t o form a pentamer is apparently essential for binding. l l o w can the unique properties of CT-B be further exploited? A number o f groups have now shown that peptidc sequences encoding antigenic determinants for potentially protective heterologous antigens can be attached to CT-B or LT-B using chemical or genetic linkage 1141. Such hybrid molecules have the ability to bind GM ,-gangliosidc yet contain antigenic determinants for CT-B and a second antigen. Such hybrid molecules are now undergoing extensive testing iri i i i~o t o ;issess their potential iis mucosal immunogens.
A second class o f potentially important proteins are the so-called invasins. lnvasins are proteins which arc required for entry of bactcria into eukaryotic cells. (,o/; ii~,u and Stilriloiic~llir have also been identified and are currently being characterized. Different invasin genes apparently express proteins which differ in the type o f cells into which they can promote bacterial invasion. Once we learn more about the structural and functional organization of these proteins, they may prove to be very useful tools for studying methods for introducing drugs into cells.
C 'or ich.sior I S
It is clear that basic studies on the mechanisms by which bacterial pathogens enter and replicate within host tissues are yielding valuablc information which could aid the development o f novel oral delivery systems.
Irltrodirctiori
Recent research in biopharmaceutics is focused upon the development o f methods to direct drugs specifically to their desired site of action. To change the biological behaviour of drugs, a variety of transport vehicles has been proposed. These vehicles include liposomes, niosomes, lectins, hormones, peptides and antibodies, but also complex systems, such as viruses and erythrocytes. Evidence for the successful delivery o f drugs iri vivo, away from the rcticulo-endothelial system, is, however. largely lacking. To avoid a primary interaction o f the transport vehicle with the reticulo-endothelial system, it was decided to learn from the endogenous biological transport systems which are physiologically utilized for triacylglycerols and cholesterol.
lriucylglycerol-rich rrnir1siori.s
Triacylglycerols arc transported by two types of vehicles, namely chylomicrons and very-low-density lipoproteins (VLDL). Exogenous fat is absorbed in the intestine and delivered to the blood circulation in so-called chylomicrons. Their size varies between 80 and 400 nm and the particle consists of a triacylglycerol core surrounded by a monolayer of phospholipids. free cholesterol and apoproteins. Removal from the circulation is a two-step mechanism, which initially involves triacylglycerol hydrolysis in extrahepatic tissues by endothelial lipoprotein lipase, with subsequently rapid uptakc o f the remnant mainly by liver parenchymal cells [ 1 ) .
Endogenous triacylglycerols are transported in VLDL, particles of a mean diameter between 28 and 75 nm, which are formed inside the liver. The metabolic fate of VLDL is Abbreviation!, uxxl: VLDL. very-low-denhity lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein. similar to chylomicrons, and after cxtrahcpatic removal of triacylglycerols, rapid uptake by livcr parenchymal cells is initiated. Up t o 15%) of the particlc may consist of cholesterol esters and this proportion may increase considerably after cholesterol feeding. On electrophoresis, this particle shows so-called p-mobility and is therefore called p-VLDL [ 2 ] . When p-VLDL is injected into rats, it becomes rapidly associated with the livcr (within 5 min) and it appears that liver parenchymal cells form the major site for p-VLDL uptake (96%) 131. Recognition of P-VLDL is coupled to internationalization o f the apolipoproteins. phospholipids and cholesterol esters [ 41.
The aforementioned biological properties of chylomicrons and VLDL make it clear that endogenous particlcs are able to circumvent recognition by macrophages, and our present research is focused upon utilizing the triacylglycerolrich particles as transport vehicles for lipophilic drugs to parenchymal liver cells.
C'holesterol(ester) -rich purtic1r.s
Cholesterol(esters) are transported in thc low-density lipoproteins (LDL) and high-density lipoproteins (HDL). LDL possess a mean diameter of 23 nm [ 5 I and 40-50'% of the LDL particle consists of cholesterol(csters). Its metabolic fate is mainly determined by the presence of specific LDLreceptors. Interest in LDL as a drug carrier has bcen stimulated by the finding that many cancer cells express a high amount of LDL receptors 161. Cancer cells presumably need much cholesterol for the formation of new membranes and the increased LDL uptake from the blood may meet this requirement. This need for LDL may be coupled t o therapeutic goals by incorporation of cytostatic drugs into LDL 171. Under normal conditions, LDL uptake is mainly exerted by liver cells and it is clear that the liver must be protected against a toxic drug-LDL complex. for cancer therapy to be effective. Happily, liver LDL receptors are subject t o effective down-regulation by diets with 0.12%) cholesterol and 20% saturated triacylglycerol 181. Figure 1 illustrates the physiological model and explains the potential role of LDL as a specific delivery system to tumour cells.
